Your browser doesn't support javascript.
loading
PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.
Guo, Zhuyan; Wang, Anlai; Zhang, Weidong; Levit, Mikhail; Gao, Qiang; Barberis, Claude; Tabart, Michel; Zhang, Jingxin; Hoffmann, Dietmar; Wiederschain, Dmitri; Rocnik, Jennifer; Sun, Fangxian; Murtie, Josh; Lengauer, Christoph; Gross, Stefan; Zhang, Bailin; Cheng, Hong; Patel, Vinod; Schio, Laurent; Adrian, Francisco; Dorsch, Marion; Garcia-Echeverria, Carlos; Huang, Shih-Min A.
Affiliation
  • Guo Z; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Wang A; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Zhang W; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Levit M; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Gao Q; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Barberis C; Sanofi, Lead Generation and Candidate Realization, Waltham, MA; and.
  • Tabart M; Sanofi Oncology, Discovery and Early Development, Vitry-Sur-Seine, France.
  • Zhang J; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Hoffmann D; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Wiederschain D; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Rocnik J; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Sun F; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Murtie J; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Lengauer C; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Gross S; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Zhang B; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Cheng H; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Patel V; Sanofi, Lead Generation and Candidate Realization, Waltham, MA; and.
  • Schio L; Sanofi Oncology, Discovery and Early Development, Vitry-Sur-Seine, France.
  • Adrian F; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Dorsch M; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
  • Garcia-Echeverria C; Sanofi Oncology, Discovery and Early Development, Vitry-Sur-Seine, France.
  • Huang SM; Sanofi Oncology, Discovery and Early Development, Cambridge, MA;
Blood ; 124(11): 1777-89, 2014 Sep 11.
Article in En | MEDLINE | ID: mdl-25006129
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blast Crisis / Gene Expression Regulation, Leukemic / Proto-Oncogene Proteins c-myc / Proto-Oncogene Proteins c-pim-1 / STAT5 Transcription Factor / Interleukin-2 Receptor alpha Subunit / Proteolysis / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Blood Year: 2014 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blast Crisis / Gene Expression Regulation, Leukemic / Proto-Oncogene Proteins c-myc / Proto-Oncogene Proteins c-pim-1 / STAT5 Transcription Factor / Interleukin-2 Receptor alpha Subunit / Proteolysis / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Blood Year: 2014 Document type: Article Country of publication: United States